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Abstract
Background: Under pathological conditions, microglia produce proinflammatory mediators which contribute to
neurologic damage, and whose levels can be modulated by endogenous factors including neurotransmitters such
as norepinephrine (NE). We investigated the ability of NE to suppress microglial activation, in particular its effects
on induction and activity of the inducible form of nitric oxide synthase (NOS2) and the possible role that IL-1β
plays in that response.
Methods:  Rat cortical microglia were stimulated with bacterial lipopolysaccharide (LPS) to induce NOS2
expression (assessed by nitrite and nitrate accumulation, NO production, and NOS2 mRNA levels) and IL-1β
release (assessed by ELISA). Effects of NE were examined by co-incubating cells with different concentrations of
NE, adrenergic receptor agonists and antagonists, cAMP analogs, and protein kinase (PK) A and adenylate cyclase
(AC) inhibitors. Effects on the NFκB:IκB pathway were examined by using selective a NFκB inhibitor and
measuring IκBα protein levels by western blots. A role for IL-1β in NOS2 induction was tested by examining
effects of caspase-1 inhibitors and using caspase-1 deficient cells.
Results: LPS caused a time-dependent increase in NOS2 mRNA levels and NO production; which was blocked
by a selective NFκB inhibitor. NE dose-dependently reduced NOS2 expression and NO generation, via activation
of β2-adrenergic receptors (β2-ARs), and reduced loss of inhibitory IkBα protein. NE effects were replicated by
dibutyryl-cyclic AMP. However, co-incubation with either PKA or AC inhibitors did not reverse suppressive
effects of NE, but instead reduced nitrite production. A role for IL-1β was suggested since NE potently blocked
microglial IL-1β production. However, incubation with a caspase-1 inhibitor, which reduced IL-1β levels, had no
effect on NO production; incubation with IL-receptor antagonist had biphasic effects on nitrite production; and
NE inhibited nitrite production in caspase-1 deficient microglia.
Conclusions: NE reduces microglial NOS2 expression and IL-1β production, however IL-1β does not play a
critical role in NOS2 induction nor in mediating NE suppressive effects. Changes in magnitude or kinetics of cAMP
may modulate NOS2 induction as well as suppression by NE. These results suggest that dysregulation of the
central cathecolaminergic system may contribute to detrimental inflammatory responses and brain damage in
neurological disease or trauma.
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Introduction
Microglial activation including the production of pro-
inflammatory cytokines and reactive oxygen species is
now recognized as a key component of several neurologi-
cal diseases including Multiple Sclerosis (MS) and Alzhe-
imer's Disease (AD); as well as other conditions in which
trauma, infection, or injury leads to inflammatory activa-
tion. Activated microglia produce the free radical NO syn-
thesized by the inducible form of the enzyme nitric oxide
synthase (iNOS or NOS2). NOS2 can be induced in
enriched cultures of microglial cells upon treatment with
proinflammatory cytokines or bacterial endotoxin [1-3],
as well as in rodent brains following peripheral or intrapa-
renchymal introduction of inflammatory inducers [4]. In
some cases NOS2 expression was dependent upon IL1β
production [5], and some anti-inflammatory treatments
were shown to reduce both microglial IL-1β as well as
NOS2 expression ([5] for review). However other studies
reported distinct, and in some cases opposite effects of
anti-inflammatory treatments upon IL-1β versus NOS2
expression [6]. Thus, the precise role for IL-1β in regulat-
ing NOS2 expression in microglia requires further study.
We demonstrated that the neurotransmitter norepine-
phrine (NE) prevents induction of NOS2 in rat cortical
astrocytes [7,8], and more recently in vivo that depletion
of NE exacerbates the cortical inflammatory response to
amyloid beta (Aβ) [9]. Similarly, others have shown that
NE reduces astroglial expression of pro-inflammatory
cytokines including IL1β and TNFα [10-13] and of cell
adhesion molecules [14]. The effects of NE appear to
involve activation of β-adrenergic receptors (β-ARs) and
elevation of intracellular cAMP, and in most cases lead to
suppression of astrocytic inflammatory responses [15].
Perturbation in NE levels, or dysfunction in NE signaling
might therefore exacerbate inflammatory responses and
thus contribute to neurological damage, for example in
AD and Parkinson's disease where noradrenergic locus
coeruleus (LC) neurons are lost [16,17], or in MS where
astrocytic β-AR expression is reduced [18,19].
Rat cortical microglia express all different types of ARs
[20], and treatment with NE results in increased levels of
cAMP within the cells which can be inhibited by the β-AR
non selective antagonist propanol [21]. However the cel-
lular effects of NE on microglial inflammatory responses
are less well characterized. NE reduced NO production in
N9 microglial cells [22] and in rat microglia [20], but
increased IL-1β mRNA in rat microglia [21]. Other agents
which increase microglial cAMP (analogs such as dibu-
tyryl-cyclic AMP (dbcAMP), activators of adenylate cyclase
(AC), or PGE2) also modulate inflammatory responses,
however in contrast to astrocytes, both up as well as down
regulation of NOS2 and IL-1β has been observed [23,24].
Since the regulation of microglial NOS2 differs from
astroglial NOS2 [25] it is not surprising that anti-inflam-
matory treatments which attenuate astrocyte NOS2 or IL-
1β may have distinct actions in microglial cells.
To better understand how NE reduces microglial inflam-
matory responses, we examined the effects of NE on
NOS2 expression in rat cortical microglial cells. We
observed that, as found for astrocytes, NE dose-depend-
ently blocked microglial NOS2 expression, via β2-ARs
activation. In the same cells, NE more potently reduced IL-
1β production, reaching close to 100% attenuation at low
concentrations of NE (1 to 10 µM). However, additional
experiments suggest that while NE inhibits both these fac-
tors, the suppression of NOS2 expression is not directly
due to the reduction of IL-1β levels. These findings indi-
cate that, at least in vitro, microglial NOS2 expression is
not dependent upon IL-1β production and therefore sug-
gest that anti-inflammatory treatments designed to reduce
IL-1β may be without effect on NOS2 levels.
Methods
Materials
Cell culture reagents (DMEM, and antibiotics) were from
Cellgro Mediatech. Fetal calf serum (FCS) and DMEM-F12
were from GIBCO Life Technologies. Lipopolysaccharide
(LPS, Salmonella typhimurium), NE, the NOS2 inhibitor
(2-amino-dihydro-6-methyl-4H-1,3-thiazine, AMT) and
the peptide aldehyde inhibitor benzyloxycarbonyl-Ile-Glu
(Ot2butyl) 2Ala-leucinal (ZIE) were from Sigma. Adrener-
gic agonists and antagonists were from BIOMOL Research
Laboratories. The protein kinase (PK) A inhibitors (KT-
5270 and H-89) and activators (dbcAMP), the AC inhibi-
tors (SQ 22536 and MDL-12,330A), the interleukin recep-
tor antagonist (IL-1ra) and the irreversible cell permeable
caspase-1 inhibitor (Ac-YVAD-CMK) were from Calbio-
chem (San Diego, CA). Taq polymerase and cDNA synthe-
sis reagents were from Promega. Anti IkBa (SC-371) rabbit
polyclonal antibody was from Santa Cruz Biotechnology
(Santa Cruz, CA). NOD.ICE-/- mice, which lack func-
tional caspase-1, and therefore do not produce mature IL-
1β or IL-18 [26] were obtained from Jackson Laboratories.
Cells
Rat cortical microglial cells were obtained as previously
described [27]. Briefly, 1 day old Sprague Dawley rats
(Charles River Laboratories) were used. The cortices were
dissected under aseptic conditions, cut into small frag-
ments, digested in 0.125% trypsin (Sigma) for 20 min at
37°C and a further 5 min in presence of 65 UI/ml of
DNAse I. Cells were plated at a density of 4 × 104 cells/cm2
in T75 flasks in 10 ml DMEM containing 10% FCS and
antibiotics (100 IU/mL of penicillin and 100 µg/mL of
streptomycin; Sigma), and incubated at 37°C in a humid-
ified atmosphere containing 5% CO2. The culture
medium was changed within 24 h, and then after 5 days.Journal of Neuroinflammation 2004, 1:9 http://www.jneuroinflammation.com/content/1/1/9
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For studies shown in figure 8, microglia were prepared
from caspase-1 deficient mice [26] using the same proce-
dure except that the incubation time with trypsin was
reduced to 5 minutes. Microglia were detached from the
astrocyte monolayer by gentle shaking 11–13 days after
the dissection and again after one week from the first
shaking. The cells were plated in 96 well plates at a density
of 3 × 105 cells/cm2, using 100 µl/well of DMEM-F12
(10% FCS and antibiotics). Under these conditions, the
cultures were 95–98% OX42-positive.
Experiments were carried out the day after the isolation
from the astrocyte monolayer in DMEM-F12. In prelimi-
nary experiments, we assessed cell viability in presence of
different concentrations of FCS, measuring lactic dehy-
drogenase (LDH) release in the incubation medium as an
index of cell toxicity. We found a significant increase in
LDH activity if the cells were incubated in serum free
medium (see also [27]) or in medium containing 1% FCS;
therefore all experiments were carried out in 10% FCS.
IL-1β Measurements
The levels of IL-1β in the incubation medium were
detected by specific ELISA assays. For rat IL-1β we used an
ELISA kit purchased by R&D System Inc and performed
according to the manufacturer's instructions. For the
assessment of IL-1β released by ICE-deficient microglial
cells, we used an ELISA specific for mouse IL-1β (BD
OptEIA™ Set, BD Bioscience).
NOS2 induction and activity measurements
NOS2 was induced in microglial cells by incubation with
bacterial endotoxin LPS. NOS2 induction was assessed
indirectly by nitrite production in the cell culture media
[28]. An aliquot of the cell culture media (80 µl) was
mixed with 40 µl of Griess reagent and the absorbance
measured at 550 nm. In preliminary studies, we found
that the LPS dependent nitrite production was greater
when cells were incubated in DMEM-F12 medium, as
compared to DMEM alone; and therefore all studies were
carried out in DMEM-F12.
In some experiments, we assessed total levels of nitrites in
the incubation media after enzymatic reduction of nitrates
to nitrites [29]. Briefly, samples were incubated with
nitrate reductase purified from Aspergillus (EC 1.6.6.2),
reduced β–NADPH, and FAD for 2 hr at 37°C to convert
nitrates into nitrites. Excess β–NADPH was removed by
incubating the samples for 30 min at 37°C in presence of
LDH from rabbit muscle (EC 1.1.1.27) and pyruvate (all
reagents from Sigma). Samples were assayed before and
after nitrate reduction by the Griess method, to obtain
nitrite levels and calculate the ratio of nitrites/nitrates. The
nitrite concentration was calculated from a NaNO2 stand-
ard curve, and complete conversion of nitrate into nitrite
was confirmed by including a standard curve of NaNO3 in
each test.
NOS2-derived NO production was measured by the oxi-
dation of the cell-permeable fluorogenic probe, 2',7-
dichlorodihydrofluorescein diacetate (H2DCF-DA) [30].
Once inside the cells, H2DCF-DA is deacetylated by
cytosolic esterases to free H2DCF, which can be oxidized
to the fluorescent compound dichlorofluorescein (DCF).
This reaction is catalyzed in vitro by the formation of the
nitrogen radical peroxinitrite, while hydrogen peroxide
and superoxide were found ineffective by themselves [31].
Since peroxinitrite is formed by reaction of NO with
superoxide, we used oxidation of H2DCF as a marker of
NO production. Briefly, cells were activated by LPS for dif-
ferent periods of time. At the end of each experiment the
incubation media was replaced by balanced salt solution
(BSS, 124 mM NaCl, 5.8 mM KCl, 10 mM dextrose, 20
mM Hepes, 0.3 mM CaCl2(H2O)2) [32]. Cells were incu-
bated in plain BSS or in BSS containing 100 µM AMT, to
selectively block NOS2 activity, for 20 min. At the end of
this pre-incubation period 20 µM H2DCF-DA was added
to the cells, which were incubated for 45 min at 37°C in
the incubator. The fluorescence signal due to H2DCF
oxidation within the cells was quantified using a plate flu-
orescence reader (GENios Multi-Detection Reader,
TECAN) using 485 nm as excitation and 535 nm as emis-
sion wavelength.
mRNA analysis
Total cytoplasmic RNA was prepared from cells using TRI-
ZOL reagent (Invitrogen); aliquots were converted to
cDNA using random hexamer primers, and mRNA levels
estimated by RT-PCR. The primers used for NOS2 detec-
tion were 1704F (5' CTG CAT GGA ACA GTA TAA GGC
AAA C-3'), corresponding to bases 1704–1728; and
1933R (5' CAG ACA GTT TCT GGT CGA TGT CAT GA-3'),
complementary to bases 1908–1933 of the rat NOS2
cDNA sequence which yield a 230 bp product. The prim-
ers used for glyceraldehyde 3- phosphate dehydrogenase
(GDH) detection were 796F (5'-GCC AAG TAT GAT GAC
ATC AAG AAG) and 1059R (5' TCC AGG GGT TTC TTA
CTC CTT GGA) which yield a 264 bp product [33]. Quan-
titative changes in mRNA levels were estimated by real
time PCR using the following cycling conditions: 35 cycles
of denaturation at 94°C for 10 s; annealing at 61°C for 15
s; and extension at 72°C for 20 s; followed by 2 min at
72°C, in the presence of SYBR Green (1:10,000 dilution
of stock solution from Molecular Probes) carried out in a
20  µL reaction in a Corbett Rotor-Gene (Corbett
Research) [34]. Relative mRNA concentrations were calcu-
lated from the take-off point of reactions using the soft-
ware included in the unit. At the end of real time PCR, the
products were separated by electrophoresis through 2%Journal of Neuroinflammation 2004, 1:9 http://www.jneuroinflammation.com/content/1/1/9
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agarose gels containing 0.1 µg/ml ethidium bromide to
ensure production of correct sized product.
Western blotting
After desired incubations, cells were lysed using 8 M urea.
The protein content in each sample was determined by
Bradford's method using bovine serum albumin as stand-
ard. Ten µg of proteins were mixed 1: 3 with 3x gel sample
buffer (150 mM Tris-HCl pH 6.8, 7.5% SDS, 45% glyc-
erol, 7.5% of bromophenol blue, 15% β-mercaptoetha-
nol), boiled for 5 min and separated through 10%
polyacrylamide SDS gels. Apparent molecular weights
were estimated by comparison to colored molecular
weight markers (Sigma). After electrophoresis, proteins
were transferred to polyvinylidene difluoride membranes
by semi-dry electrophoretic transfer. The membranes were
blocked with 10% (w/v) low-fat milk in TBST (10 mM
Tris, 150 mM NaCl, 0.1% (w/v) Tween-20, pH 7.6) for 1
h, and incubated in the presence of anti-IκBα antibody (at
1:1,500 dilution) overnight with gentle shaking at 4°C.
The primary antibody was removed, membranes washed
4 times in TBST, and further incubated for 1 h at room
temperature in the presence of anti-rabbit IgG-HRP sec-
ondary antibody, diluted 1: 7,000. Following 4 washes in
TBST, bands were visualized by incubation in enhanced
chemiluminescence reagents for 1 min and exposure to X-
ray film for 5 min.
Data analysis
All experiments were done at least in triplicate. Data are
analyzed by one or two way ANOVA followed by Dun-
nett's multiple comparison or Bonferroni post hoc tests
and P values < 0.05 were considered significant.
Results
LPS induces NOS2 expression in microglia
As shown by several groups, incubation of enriched cul-
tures of rat cortical microglial cells with a low dose of LPS
(1 ng/ml) led to a time-dependent increase in nitrite accu-
mulation in the cell culture media. This concentration of
LPS did not induce significant microglial cell death
(assessed by LDH release); nor did higher concentrations
of LPS result in significantly higher levels of nitrite pro-
duction (data not shown). Nitrite levels were undetecta-
ble in control samples incubated for up to 24 hr, whereas
LPS induced significant nitrite levels at 8 hr and 24 hr
(0.49 and 3.9 nmole per 100,000 cells, respectively, Fig-
ure 1A); or approximately 2.1 µM nitrite accumulated per
LPS increases microglial nitrite production Figure 1
LPS increases microglial nitrite production. Rat microglia cells were incubated in the presence (▲ ) or absence (❍ ) of 
LPS (1 ng/ml) for indicated times. NO production was assessed (A) indirectly by measuring nitrite levels in the incubation 
medium; or (B) directly by the oxidation of H2DCF added to the cells at the end of the experiment. For DCF studies, in each 
experimental group NOS2 activity was inhibited in parallel samples by preincubating cells 20 min with the selective NOS2 
inhibitor, 2-amino-dihydro-6-methyl-4H-1,3-thiazine (AMT, 100 µM). Data are means ± s.e.m. of 3 different experiments. *** 
and *, P < 0.001 and 0.05 versus control; two-way ANOVA followed by Bonferroni's post hoc test.Journal of Neuroinflammation 2004, 1:9 http://www.jneuroinflammation.com/content/1/1/9
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hr per 100,000 cells (10 µg protein). Measurements using
the fluorescent reporter H2DCF-DA in the presence or
absence of a selective NOS2 inhibitor (AMT, 100 µM)
showed that NO production could be detected as soon as
4 hr after incubation with LPS and remained relatively
unchanged for up to 24 hr incubation (Figure 1B).
NE inhibits nitrite accumulation and NO production
Microglia were incubated with LPS and varying concentra-
tions of NE (Figure 2A). Co-incubation with NE dose-
dependently reduced nitrite accumulation (measured
after 24 hr incubation), with statistically significant inhi-
bition occurring as low as 0.1 µM NE, and maximal
inhibition reaching about 30% at 10 µM NE. Measure-
ments of NO using H2DCF-DA showed that NE reduced
NOS2-derived NO after 4 hr of incubation, although at
this time point significant inhibition was observed only at
the higher (10 µM) NE concentration used (Figure 2B).
Measurements of nitrite and nitrate levels (Figure 3)
showed that the ratio of nitrite to nitrate (indicative of
chemical breakdown) was unaffected by treatment with
NE, ruling out that the reduction of nitrite accumulation
due to NE was not due to increased conversion to nitrate.
NE effects are mediated by β2-ARs and may involve cAMP
The inhibition of nitrite accumulation by NE was mim-
icked by the β-AR agonist isoproterenol used between 0.1
and 10 µM (Figure 4A), and by the cAMP mimetic
dbcAMP (Figure 4B). The inhibitory effects of NE were not
reversed by the α-AR antagonist phenoxybenzamine (PB,
Figure 5A) but were completely reverted using either a
non-selective β-AR (propanolol, Figure 5A) or a selective
β2-AR (ICI-118,551; Figure 5B) antagonist. Measure-
ments of intracellular cAMP levels confirmed that NE (10
µM) significantly increased (approximately 10-fold versus
control cells) cAMP levels between 15 and 60 minutes of
incubation (not shown).
Since activation of PKA is mediated by cAMP, we tested a
role for PKA in mediating NE inhibitory effects (Figure
Microglial NOS2 activity is reduced by NE Figure 2
Microglial NOS2 activity is reduced by NE. Microglia were incubated with LPS and indicated concentrations of norepine-
phrine (NE). NO production was measured as in figure 1, (A) indirectly by nitrite levels measured after 24 hr; or directly by 
DCF fluorescence after 4 hr. In B, data are expressed as net relative fluorescence units (RFU) which is calculated as the differ-
ence between total RFU and the RFU values obtained by pre-blocking NOS2 activity in parallel samples with AMT (100 µM). 
Data are means ± s.e.m. of 3 experiments. ***, P < 0.001 versus LPS alone; one-way ANOVA.Journal of Neuroinflammation 2004, 1:9 http://www.jneuroinflammation.com/content/1/1/9
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6A). However, co-incubation with the selective PKA
inhibitor KT-5720 (Figure 6A) or compound H89 which
inhibits both PKA and PKC (Figure 6B) did not reverse NE
effects, suggesting that PKA activation does not play a
major role in reducing NOS2 activity (or expression).
Moreover, both inhibitors when used alone reduced
nitrite accumulation due to LPS, suggesting that PKA and/
or PKC activation may in fact play a role in potentiating
microglial NOS2 induction.
To examine a role for cAMP in mediating NE actions, we
treated microglia cells with two different AC inhibitors,
SQ 22536 (IC50= 200 µM) and MDL-12,330A (IC50= 250
µM). Unexpectedly, in these cells inhibition of AC activity
reduced LPS induced nitrite production (Figure 7A) and
NOS2 expression (Figure 7B), and SQ 22536 further
potentiated NE inhibitory effects (Figure 7A).
NE reduces NOS2 mRNA and increases IkBα levels
Quantitative RT-PCR analysis (Figure 8) showed that LPS
increased NOS2 mRNA steady state levels approximately
15-fold versus control values after 4 hr of incubation, and
further increased levels (to roughly 50-fold control levels)
at 24 hr incubation. The presence of NE reduced the
increase in NOS2 mRNA levels at both 4 and 24 hr,
suggesting an effect of NE at the transcriptional and or
post-transcriptional level.
In astrocytes, the suppression of NOS2 by NE involves
modulation of the NFκB:IκB signaling system [33]. In
microglia, nitrite production was also dependent upon
NFκB activation, since treatment with the NFκB inhibitor
ZIE dose-dependently reduced nitrite accumulation (Fig-
ure 9A). ZIE is a highly selective inhibitor of the 26S pro-
teasome which blocks IκBα degradation and NFκB
translocation into the nucleus [35]. In fact LPS induced a
rapid loss of inhibitory IκBα protein (Figure 9B), which is
affected by NE treatment. In the presence of NE, the reduc-
tion in IκBα protein levels occurring after 30 minutes
incubation was less than that in control cells, while after
90 minutes NE caused an increase in IκBα levels. This sug-
gests that, similar to what is observed in astrocytes [34],
NE may increase IκBα re-synthesis.
NE reduces IL-1β release
As previously reported [12,36,37], LPS increased micro-
glia IL-1β production (Figure 10A). As for nitrite produc-
tion, co-incubation with NE (10 µM) reduced IL-1β
release; however the magnitude of suppression was
greater (approximately 80% inhibition) than the 30%
suppression of nitrites observed. Incubation of cells with
NE alone led to a small but non-significant IL-1β release
after 7 hr. In contrast to nitrite reduction, maximal effects
of NE on IL-1β levels were observed even at the lowest
concentration (0.1 µM) tested (Figure 10B).
Effects of blocking IL-1β production on NOS2 expression
The above results suggested a link between microglial
NOS2 expression and IL-1β production. However, incu-
bation with a caspase-1 inhibitor (Figure 11A) reduced IL-
1β production by 33% (Figure 11B) but had no effect on
NO production (Figure 11B). Results using the IL-1ra
were conflicting, since although we found a reduction
(24%) of LPS-induced nitrite accumulation at the highest
concentration tested (100 ng/mL), we found an increase
(between 24–33%) at lower concentrations (10–30 ng/
mL; data not shown). To further test an involvement of IL-
1β in the induction of NOS2 by LPS, we used microglial
cells derived from caspase-1 deficient mice which cannot
produce the mature form of IL-1β. In these cells, LPS (10–
1000 ng/ml) induced similar levels of nitrite production
as did wild type cells; and the inhibitory effects of NE were
maintained both at the highest concentration of LPS
(Figure 11C) and at the lower ones (not shown).
Together, these results suggest that the inhibition by NE is
not primarily mediated via effects on IL-1β production.
NE does not modify nitrite conversion to nitrate Figure 3
NE does not modify nitrite conversion to nitrate. 
Microglia cells were incubated with LPS (1 ng/ml) plus or 
minus 10 µM NE. After 24 hr, the levels of nitrite (open bars) 
and nitrate (filled bars) in the cell culture media were deter-
mined. ***, P < 0.001 versus LPS alone (NO2); §§, P < 0.05 
versus LPS alone (NO3). The ratio of nitrite to nitrate in LPS 
treated cells was 0.91 ± 0.02, and in LPS/NE treated cells was 
0.79 ± 0.03 (n = 3).Journal of Neuroinflammation 2004, 1:9 http://www.jneuroinflammation.com/content/1/1/9
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Discussion
Consistent with previous reports, in the present study we
show that rat cortical microglia can be activated in vitro by
low doses of LPS leading to NOS2 expression, NO produc-
tion and nitrite accumulation. Under our experimental
conditions, co-incubation with NE (0.1–10 µM) inhibited
LPS-dependent NOS2 expression and NO and nitrite
production, via activation of β2-ARs most likely mediated
by elevation of intracellular cAMP. Although NE has a
high affinity for, and at low doses (100 nM to 1 µM) can
increase cAMP via microglial β1 and β3 ARs, even greater
increases in cAMP were found at higher (1–10 µM) NE
concentrations which are needed to activate β2-ARs [21].
Thus, the amounts of NE needed to reduce NOS2
expression may reflect a requirement to activate β2-ARs in
our studies, although other non-receptor mediated effects
cannot be ruled out. Previous studies of adrenergic regula-
tion of microglial NOS2 are limited: isoproterenol
decreased NO release [38]; and in one study [20], NE,
terbutaline (a β2-AR agonist), dobutamine (a β1-AR ago-
nist) as well as phenylephrine (an α1-AR agonist) all
reduced NO production despite different effects on cAMP
elevation; suggesting that adrenergic stimulation can
attenuate NOS2 irrespective of effects on cAMP.
Our results are consistent with several reports showing
that intracellular levels of cAMP modulate microglial
NOS2 expression. NOS2 expression was reduced by cAMP
analogs in microglia [42]; by PGE2 (as well as FSK and
dbcAMP) in enriched microglia [43,44]; and in mixed
neuron:microglial co-cultures [36]. Microglial NOS2 was
also reduced by treatment with phosphodiesterase (PDE)
inhibitors [38,42-45]; as well as other agents which
increase cAMP, including melanocortin peptides [46],
and conditioned media from T. gondii infected astrocytes
[48]. However, NOS2 is not always suppressed by ele-
vated cAMP, and there are several studies showing that in
contrast to being inhibitory, cAMP potentiates NOS2
expression [15]. For example, dbcAMP or IBMX treatment
increased microglial NOS2 expression and activity due to
Aβ [23]. The potentiating effects of cAMP appear to be
mediated through activation of C/EBP family proteins
which can be stimulatory [47], rather than through activa-
tion of CREB proteins which may be inhibitory [8]; and in
macrophages may include activation of other kinases
Inhibitory Effects of NE are mediated by β-ARs and replicated by cAMP Figure 4
Inhibitory Effects of NE are mediated by β-ARs and replicated by cAMP. Microglia were incubated with LPS (1 ng/ml) 
and indicated concentrations of (A) isoproterenol or (B) dibutyryl-cyclic AMP (dbcAMP). Nitrite levels were measured after 24 
hours. ***, P < 0.001 versus LPS alone.Journal of Neuroinflammation 2004, 1:9 http://www.jneuroinflammation.com/content/1/1/9
Page 8 of 15
(page number not for citation purposes)
including PKC isoforms and p38 MAPK [49]. Hence,
activation of distinct cAMP-dependent transcription fac-
tors could account for observation of both activation as
well as suppression by cAMP in microglial cells.
It should be pointed out that studies using dbcAMP
should be interpreted cautiously since dbcAMP must first
be metabolized to its active form, monobutyryl cAMP, a
reaction catalyzed by intracellular esterases as well as
extracellularly in the presence of serum, and that also
releases the butyryl group from the 5'-position. The anti-
inflammatory effects of dbcAMP on NO production could
therefore be due, in part, to production of sodium
butyrate which in rat primary microglial cells can reduce
NO production and IL6 and TNFα release [39].
Nevertheless, findings that the effects of NE are mediated
via β2-ARs which primarily increase intracellular cAMP,
and also are mimicked using the βAR agonist isoprotere-
nol are consistent with the idea that NE actions involve
increases in cAMP.
Although PKA is a primary target for activation by cAMP,
we found that selective PKA inhibitors did not reverse the
inhibitory effects of NE, suggesting that other cAMP-
dependent signaling pathways, such as the newly charac-
terized EPAC/RAP system [40] may mediate NE inhibitory
actions in microglia. However interpretation of results
with PKA inhibitors are complicated by the fact that these
inhibitors blocked LPS-dependent nitrite production (Fig-
ure 6B), suggesting a role for PKA activation in NOS2
induction.
Similarly, our results show that the AC inhibitor SQ22536
did not reverse NE actions, and by itself reduced LPS-
induced NOS2 activity and expression (Figure 7). This
finding is in contrast with previous studies showing no
effects of this agent (or other AC inhibitors) on NOS2
induction, yet able to reverse NOS2 suppression due to
activation of the prostaglandin EP2 receptors by PGE2
[41]. However, in the same study contradictory effects of
AC activation on NOS2 were observed, since sulprostone,
a potent agonist for the EP1 and EP3 receptors which
inhibits AC activity, inhibited LPS-induced nitrite produc-
Inhibitory Effects of NE are mediated by β2-ARs Figure 5
Inhibitory Effects of NE are mediated by β2-ARs. Microglia were incubated with LPS (1 ng/ml) alone or with NE (1 µM), 
and in the presence of (A) the α-AR antagonist phenoxybenzamine (PB, 10 µM) or the indicated amount of β-AR antagonist 
propanolol (Prop); or (B) indicated concentrations of the selective β2-AR antagonist ICI 118,551. Nitrite levels were measured 
after 24 hr. ***, P < 0.001 versus LPS alone; §§§ and §, P < 0.001 and 0.05 versus LPS plus NE.Journal of Neuroinflammation 2004, 1:9 http://www.jneuroinflammation.com/content/1/1/9
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tion; furthermore nitrite production was also increased at
the higher concentrations of isoproterenol (>100 nM),
the AC activator forskolin (FSK, > 100 µM) and dbcAMP
(>10 µM). AC activators also had contrasting effects on Aβ
induced nitrite production in microglia, where low doses
of forskolin (10 to 50 µM) increased NO release, and a
higher dose (100 µM) reduced NO release [23]. An under-
standing of the contrasting effects of PKA and AC inhibi-
tors on nitrite production and NOS2 expression may
therefore help to explain reported divergent effects of
cAMP on microglial NOS2.
The effects of increasing cAMP levels on microglial IL-1β
production and expression are also conflicting. Thus, Si et
al. [50] showed that the PDE inhibitor propentofylline
reduced LPS induced TNFα and IL-1β release; Caggiano
and Kraig [12,51] showed that PGE2 acting via EP2
receptors (and increased cAMP) reduced IL-1β produc-
tion; and Cho et al. [13] showed that the dopamine
metabolite NAMDA which increases cAMP and CREB acti-
vation reduced IL-1β mRNA levels. In contrast, Hetier [24]
found that the β-AR agonist isoproterenol reduced LPS
induced IL-1β as well as TNFα production, however while
TNFα mRNA was reduced, IL-1β mRNA was increased.
Tomozawa et al. [52] similarly found that isoproterenol
(and dbcAMP) increased IL-1β mRNA in microglial
(although not in astrocytes); and Petrova et al. [11]
reported that PGE2 also reduced IL-1β secretion, but
increased IL-1β mRNA levels. More recently, Woo et al
[53] showed that dbcAMP reduced TNFα expression, but
increased IL-1β expression in BV2 cells; and Tanaka et al.
[21] showed in that various β1- and β2-AR agonists alone
could increase IL-1β mRNA levels in rat microglia. Our
data is therefore the first to demonstrate the effects of an
endogenous neurotransmitter on NOS2 expression and
IL-1β levels in stimulated microglial cells.
The suppression by NE of IL-1β production was similar to
that seen for NOS2, which suggested that the ability of NE
to reduce NOS2 may be related to its ability to reduce IL-
1β. However, several features suggest that these may be
independent events. Thus, in contrast to suppression of
NOS2, the effects of NE on IL-1β were observed at concen-
trations lower than that needed for maximal inhibition of
NOS2 expression, and resulted in greater extent of inhibi-
tion (over 80% inhibition of IL-1β versus 30% of NO or
nitrite production). Furthermore, NE was able to reduce
nitrite production in caspase-1 deficient cells (Figure 10C)
demonstrating that effects of NE on IL-1β are not
necessary to observe effects on NOS2. Several previous
reports suggest distinct regulation of microglial NOS2 and
IL-1β. Thus, microglial cells cultured in the presence of
Protein Kinase A does not mediate Effects of NE Figure 6
Protein Kinase A does not mediate Effects of NE. Microglia were incubated with LPS (1 ng/ml) alone or with NE (1 µM), 
and in the presence of (A) the selective PKA inhibitor KT5720; or (B) the PKA and PKC inhibitor H89. Nitrite levels were 
measured after 24 hr. ***, P < 0.001 versus LPS alone; §§§, P < 0.001 versus LPS plus NE.Journal of Neuroinflammation 2004, 1:9 http://www.jneuroinflammation.com/content/1/1/9
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astrocytes lost their ability to produce NOS2 in response
to LPS, although their IL-1β release was unaffected [54].
Petrova et al. [11] and Si et al. [50] showed cAMP depend-
ent reductions in IL-1β production with no effect on NO
production; and Woo et al [53] showed increased IL-1β
expression due to dbcAMP with no effect on NO produc-
tion. More recently, treatment of LPS activated microglia
with malonic acid C60 derivatives reduced NOS2 mRNA
expression, although these same reagents increased the
release of IL-1β [55]. From these studies, it is clear that
there is no necessary concordance between the regulation
of IL-1β expression (or production) and that of NOS2
expression (or activity).
In general, the role that IL-1β plays in inducing glial
(astrocytes or microglial) NOS2 is not clear. In astrocytes,
IL-1β in combination with other cytokines (IFNγ and/or
TNFα) can induce rodent NOS2 [25,56], and a few reports
suggest that IL-1β alone may induce rodent astrocyte
NOS2 [57]. In contrast, in human fetal and adult
astrocytes, IL-1β alone can induce NOS2 [58,59] which is
greatly increased by other cytokines [60]. Although astro-
cyte NOS2 induction can, in some cases, be reduced by
treatment with IL-ra (hypoxia, [61]; using CM obtained
from Gp41 activated of microglia, [62]; using Aβ stimula-
tion, [63]) it is likely that other factor(s) are released
which contribute to NOS2 induction. In contrast to astro-
cytes, there are no clear reports to indicate that IL-1β alone
will induce microglial NOS2, and in fact human
microglial appear more refractory to NOS2 inducers than
do rodent cells [58]. Our results are consistent with the
conclusion that the LPS induced IL-1β does not play an
important role in mediating microglial NOS2 expression.
The molecular mechanism(s) by which NE reduces micro-
glial NOS2 expression and IL-1β production and expres-
sion are not yet known. Work from several laboratories
has shown in glial cells that LPS rapidly activates PK cas-
cades which lead to phosphorylation of inhibitory IκB
proteins, their degradation by the 26S proteasome, and
subsequent activation of NFκB [64], necessary for the
expression of pro-inflammatory genes [65]. We observed
that LPS induced rapid loss of the microglial IκBα protein,
while co-incubation with NE reduced that loss and more-
over increased IκBα levels after longer times. Several
reports suggest that increases in cAMP are associated with
Adenylate cyclase activation mediates LPS induced NO production Figure 7
Adenylate cyclase activation mediates LPS induced NO production. (A) Microglia were incubated with LPS (1 ng/ml) 
alone or with NE (1 µM), and in the presence of the AC inhibitor SQ 22536 (SQ); or with LPS in presence of the irreversible 
cell permeable AC inhibitor MDL-12,330A (MDL). *** and **, P < 0.001 and 0.01 versus LPS alone. (B) Total cytosolic RNA 
was prepared from control microglia, or microglia incubated for 24 h with 1 ng/ml of LPS in presence of 200 µM SQ22536, or 
10 µM NE or both SQ and NE and used for Q-PCR analysis of NOS2 mRNA. Data are expressed as percentage of LPS (100%). 
***, P < 0.001 versus LPS alone; one-way ANOVA.Journal of Neuroinflammation 2004, 1:9 http://www.jneuroinflammation.com/content/1/1/9
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increased levels of IκBα [66-68], and we demonstrated
that NE directly increases transcription of the IκBα gene in
astrocytes and reduces the overall magnitude of IkBa
degradation [34]. Taken together these data suggest that
the inhibitory effects of NE in microglia may also be medi-
ated in part by interference with the NFkB:IkB signaling
pathway.
The in vivo relevance of noradrenergic regulation of
inflammatory gene expression, is suggested by observa-
tions that the noradrenergic neurons of the LC are dam-
aged or lost in AD [69], leading to a loss (or at least a
transient loss) in noradrenergic signaling within projec-
tion areas. A possible perturbation in noradrenergic sign-
aling is also implicated in MS, since it has been shown
that treatment with β-AR agonists [70,71] can provide
protection in animal models of MS, and more recently
that the levels of β2-ARs in astrocytes are decreased in MS
patients as compared to healthy controls [72]. We recently
demonstrated that LC loss increases both the magnitude
as well as the duration of the inflammatory responses in
vivo including the extent of microglia activation [73]. Fur-
thermore, we showed that central NE depletion led to a
dramatic decrease in cortical levels of the IkBa protein,
consistent with the idea that NE normally keeps the IkBa
gene transcriptionally active [34]. Together with the
knowledge that IL-1β plays a prominent role in the patho-
genesis of neurodegenerative diseases, such as AD [74],
and in view of the fact that microglial NOS2 expression is
implicated in the damage occurring in MS [75,76], AD
[77] and cerebral ischemia [78,79], it may be of value to
consider possible therapeutic strategies to increase micro-
glial β-AR activation or intracellular cAMP levels.
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Microglial NOS2 mRNA is reduced by NE Figure 8
Microglial NOS2 mRNA is reduced by NE. Total 
cytosolic RNA was prepared from control microglia, or 
microglia incubated with LPS (open bars) or LPS plus 1 µM 
NE (filled bars), and used for Q-PCR analysis of NOS2 
mRNA. Data are means ± s.e.m of 2 replicates per group, 
and are the values calculated for NOS2 mRNA levels relative 
to control (non-stimulated) cells. *** and **, P < 0.001 and 
0.01 versus LPS alone; two-way ANOVA followed by Bonfer-
roni's post hoc test.
NE reduces LPS-induced IkBα loss Figure 9
NE reduces LPS-induced IkBα loss. (A) NOS2 expres-
sion requires NFkB activation. Microglia were incubated with 
LPS (1 ng/ml) and the indicated concentration of the selective 
NFkB inhibitor ZIE. Nitrite levels were measured after 24 hr 
incubation. **, P < 0.01 versus LPS alone. (B) Microglial were 
incubated with LPS or LPS and NE (1 µM), and at the indi-
cated time points, cytosolic lysates were examined for the 
presence of IkBα protein by western blot analysis. The gel 
shown is representative of experiments done on 3 separate 
microglial preparations.Journal of Neuroinflammation 2004, 1:9 http://www.jneuroinflammation.com/content/1/1/9
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NE inhibits LPS dependent IL-1β production Figure 10
NE inhibits LPS dependent IL-1β production. (A) Microglia were incubated in medium alone (❍ ), 1 ng/ml LPS (● ), 10 
µM NE (Ќ), or LPS plus NE (▼ ) and IL-1β levels were measured by ELISA at the indicated times. Data are means ± s.e.m. and 
are expressed as pg of IL-1β/ml. ***, P < 0.001 versus control; §§§ and §§, P < 0.001 and 0.01 versus LPS alone (n = 3); two-way 
ANOVA followed by Bonferroni's post hoc test. (B) Microglia were incubated in presence of 1 ng/ml LPS plus the indicated 
amounts of NE, and IL-1β levels measured by ELISA after 4 hours. Data are presented as % of the response to LPS alone (100% 
= 1160 ± 80 pg/ml). ***, P < 0.001 versus LPS alone (n = 3); one-way ANOVA followed by Dunnett's multiple comparison test.
Effect of Caspase-1 inhibition on NOS2 activity Figure 11
Effect of Caspase-1 inhibition on NOS2 activity. Microglia were incubated with 1 ng/ml LPS and the indicated concentra-
tions of the caspase-1 cell-permeable irreversible inhibitor, Ac-YVAD-CMK. After 4 hr, (A) IL-1β levels in the incubation 
media were assessed by ELISA; and (B) NOS2 activity in the cells measured by increase in net DCF fluorescence (total RFU 
minus the RFU obtained by preincubating cells with 100 µM AMT NOS2 inhibitor). The data are means ± s.e.m of 3 experi-
ments; the values for IL-1β are presented as % of the response to LPS alone (100% = 2520 ± 150 pg/ml). ***, P < 0.001 versus 
LPS alone. (C) Caspase-1 deficient microglia were incubated in 1 µg/ml LPS with 0 or 10 µM NE. Nitrite levels were measured 
after 24 hours. Data are means ± s.e.m. of 3 experiments. ***, P < 0.001 versus LPS alone.Journal of Neuroinflammation 2004, 1:9 http://www.jneuroinflammation.com/content/1/1/9
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